Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

Jacqueline Vuky, Richard Yu, Lawrence Schwartz, Robert J. Motzer

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)327-330
Number of pages4
JournalInvestigational New Drugs
Volume20
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Karnofsky Performance Status
Liver Function Tests
Life Expectancy
Exanthema
Renal Insufficiency
Anemia
Diarrhea
Appointments and Schedules
Neoplasm Metastasis
arsenic trioxide
Brain

Keywords

  • Arsenic trioxide
  • Metastatic renal cell carcinoma
  • Phase II trial

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. / Vuky, Jacqueline; Yu, Richard; Schwartz, Lawrence; Motzer, Robert J.

In: Investigational New Drugs, Vol. 20, No. 3, 2002, p. 327-330.

Research output: Contribution to journalArticle

Vuky, Jacqueline ; Yu, Richard ; Schwartz, Lawrence ; Motzer, Robert J. / Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. In: Investigational New Drugs. 2002 ; Vol. 20, No. 3. pp. 327-330.
@article{e0de0a98b37646289e55b31f2aa3a42c,
title = "Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma",
abstract = "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70{\%}, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36{\%}), anemia (21{\%}), renal insufficiency (14{\%}), rash (7{\%}), and diarrhea (7{\%}). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.",
keywords = "Arsenic trioxide, Metastatic renal cell carcinoma, Phase II trial",
author = "Jacqueline Vuky and Richard Yu and Lawrence Schwartz and Motzer, {Robert J.}",
year = "2002",
doi = "10.1023/A:1016270206374",
language = "English (US)",
volume = "20",
pages = "327--330",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

AU - Vuky, Jacqueline

AU - Yu, Richard

AU - Schwartz, Lawrence

AU - Motzer, Robert J.

PY - 2002

Y1 - 2002

N2 - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

AB - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

KW - Arsenic trioxide

KW - Metastatic renal cell carcinoma

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0036021225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036021225&partnerID=8YFLogxK

U2 - 10.1023/A:1016270206374

DO - 10.1023/A:1016270206374

M3 - Article

C2 - 12201495

AN - SCOPUS:0036021225

VL - 20

SP - 327

EP - 330

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -